Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality® ▼ (galcanezumab): Storage and Stability

Store the medicine in a refrigerator (2°C to 8°C). Do not freeze. Store in the original package in order to protect from light.

Do not shake as this can damage the medicine inside the device.1,2,3,4

Product in the Possession of the Patient or Caregiver

Emgality may be stored unrefrigerated for single period up to 7 days when stored at temperatures up to 30 °C. If the device is stored at a higher temperature or for a longer period it must be discarded.2

Once the device has been intentionally stored at room temperature, do not return to the refrigerator and discard, if unused, within 7 days.4

Do not use this medicine if you notice that the device is damaged, or the medicine is cloudy or has particles in it.2

Do not use this medicine after the expiry date which is stated on the label and on the carton after “EXP.” The expiry date refers to the last day of that month.2

Keep this medicine out of the sight and reach of children.2

Product in the Possession of the Healthcare Provider

The 7-day room temperature storage is reserved for patient/caregiver use only.4

Healthcare facilities (e.g. doctor’s office, pharmacy, etc.) and wholesalers or distribution centers cannot use any part of the patient’s 7-day room temperature storage time.4

If Emgality is exposed to temperatures outside the recommended storage and handling range, Lilly personnel can perform a product quality assessment to determine potential impact to the product. This product quality assessment is not intended to replace the recommended storage or handling conditions for the product.

Lilly can only assess the potential impact of the temperature exposure to the product on a case-by-case basis and after the event has occurred. You must be able to provide the batch number, the amount of time, what temperatures and what type of light (if applicable) the Emgality was exposed to outside of the recommended storage and handling conditions. The product quality assessment must occur after the temperature or light exposure has ended and the products have been returned to the recommended storage conditions.

References

  1. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

  2. Emgality [package leaflet]. Eli Lilly Nederland B.V., The Netherlands.

  3. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.

  4. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: February 18, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question